Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / CORE Biomedicine

CORE Biomedicine

Series AUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$21.0Msum of rounds with a disclosed amount only
Named investors
2
Financing history
1 rounds
  1. Jul 28, 2026
    Series A · $21.0M (disclosed)
    UTokyo Innovation Platform Co (lead)Mitsubishi UFJ Capital Co (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics”
Investors on record
2 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Jul 28, 2026
    CORE Biomedicine announced Series A of $21,000,000, led by UTokyo Innovation Platform Co
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company